Neo-antigen Targeted Cancer Immunotherapy

These neo-antigen targeted immunotherapies are being investigated in RAS-mutated patients across various tumor types including pancreatic cancer, colorectal cancer, lung cancer or malignant melanoma. The immunotherapies induce mutant RAS specific T-cell immune responses and are ideal for combining with check point inhibitors.

TG01

TG01 is Targovax’s lead RAS immunotherapy product - a neo-antigen therapeutic anti-cancer vaccine targeted at the difficult to treat RAS mutations found in over 90% of pancreatic cancer, 50% of colorectal cancer and 20-30% of all cancers. Initially being tested in the clinic in pancreatic cancer, it is hoped that by inducing mutant RAS specific T-cell immune responses in cancer patients with RAS mutations, TG01 will prolong time to cancer progression, increase survival and improve safety and tolerability compared to chemotherapy and other immunotherapies.

TG01 has recently completed a Phase I/II clinical trial in resected pancreatic cancer. The trial enrolled a total of 32 patients, split in two patient cohorts receiving different dosing regimens. The first cohort consists of 19 patients, receiving TG01 injections, before, during and after adjuvant chemotherapy treatment, and the second cohort consists of 13 patients on a reduced dosing regimen, with TG01 injections before and after, but not during, chemotherapy treatment.

For the first cohort the two-year survival rate was 68% (13/19 patients) and the median OS 33.1 months. For the second cohort the two-year survival rate was 77% (10/13 patients) and the median OS has not yet been reached.

Combining the results from the two cohorts, mOS for all 32 patients was 33.4 months, which is nearly six months better than the mOS of 27.6 months for gemcitabine alone reported in the recent ESPAC4 trial (Neoptolemos JP et al.; The Lancet; 389:1011-1024 (2017)).

Summarizing the top-line data for the 32 patients in this phase I/II trial, the following was observed:

  • • Median overall survival (mOS) was 33.4 months

  • • 94% of patients (30/32) were alive one year after surgery

  • • 72% of patients (23/32) were alive two years after surgery

  • • 90% of patients (29/32) demonstrated mutant RAS-specific immune activation

Targovax will seek to continue to monitor the treated patients in order to assess long-term survival.

TG02

TG02, Targovax’s second generation mutRAS neo-antigen cancer vaccine, is currently being studied in a Phase 1b clinical trial in colorectal cancer, in combination with the immune checkpoint inhibitor Keytruda.

TG03

TG03 is a further immuno-oncology approach in discovery.

Jon Amund Eriksen picture

Jon Amund Eriksen
Special Advisor

Even though RAS mutations were identified as key drivers of cancer progression and treatment resistance several decades ago, effective treatments of RAS-mutated cancers have yet to be made available for patients. We hope that our RAS-targeted immunotherapy will be a practice changing cancer treatment approach.

See publications on neo-antigen targeted immunotherapies.